Substance / Medication

Amlexanox

Overview

Active Ingredient
amlexanox
RxNorm CUI
46307

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

Clinical Trials

12 trials linked to this intervention

12
Total Trials
8
Recruiting
1
With Results

Research Evidence

Published studies and systematic reviews

Sort:
Amlexanox is as effective as dexamethasone in topical treatment of erosive oral lichen planus: a short-term pilot study.
Fu Ji, Zhu Xiaohan, Dan Hongxia et al. · Oral Surg Oral Med Oral Pathol Oral Radiol · 2012
PMID: 22668622RCT
The efficacy of amlexanox OraDisc on the prevention of recurrent minor aphthous ulceration.
Murray B, Biagioni P A, Lamey P-J · J Oral Pathol Med · 2006
PMID: 16430743Observational
Interaction of S100 proteins with the antiallergic drugs, olopatadine, amlexanox, and cromolyn: identification of putative drug binding sites on S100A1 protein.
Okada Miki, Tokumitsu Hiroshi, Kubota Yasuo et al. · Biochem Biophys Res Commun · 2002
PMID: 11944917Observational
TBK1 inhibitor amlexanox exerts anti-cancer effects against endometrial cancer by regulating AKT/NF-κB signaling.
Shin Jiha, Lim Jihoon, Han Daewon et al. · Int J Biol Sci · 2025
PMID: 39744441PreclinicalFull text (PMC)
Amlexanox targeted inhibition of TBK1 regulates immune cell function to exacerbate DSS-induced inflammatory bowel disease.
Hui Lu, Huang Meng-Ke, Dai Qing-Kai et al. · Clin Exp Immunol · 2025
PMID: 39248363PreclinicalFull text (PMC)
Amlexanox alleviates renal inflammation and fibrosis by inhibiting cGAS/STING/TBK1 and TGF-β1/Smad signaling.
Gairola Shobhit, Kaundal Ravinder K · Eur J Pharmacol · 2025
PMID: 41110750Preclinical
Combined amlexanox and anti-MCP-1 therapy suppresses tumor progression in a murine Lewis lung carcinoma model.
Liu Xiaodan, Dong Xue, Wei Jiaona et al. · Anticancer Drugs · 2025
PMID: 40626452Preclinical
Amlexanox Ameliorates Traumatic Brain Injury by Restoring Autophagy-Lysosomal Function via cAMP Signaling Modulation.
Woo Seo Young, Park Min Kyu, Kho A Ra et al. · Int J Biol Sci · 2025
PMID: 40765831PreclinicalFull text (PMC)

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Health Goals

Goals connected through associated conditions

Quick Facts

Type
Substance / Medication
Fully Specified Name
Amlexanox (substance)
SNOMED CT
108897008
UMLS CUI
C0103049
RxNorm CUI
46307

Clinical Data

This intervention maps to 9 entities in the Ltrl knowledge graph.

4
Conditions
2
Biomarkers
2
Specialists
0
Symptoms
12
Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.